AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Japanese patients living in Japan with allergic conjunctivitis with itching and redness

• Able and willing to discontinue wearing any contact lenses during the study period.

Exclusion Criteria:

• Eye surgical intervention and/or a history of refractive surgery within 6 months

• History of retinal detachment, diabetic retinopathy, or progressive retinal disease

• Presence of active eye infection (bacterial, viral, or fungal)

• History of an eye herpetic infection

• Use of corticosteroids within 6 months or anticipated use during the study.